×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Legend Biotech Co. (NASDAQ:LEGN) Receives Average Recommendation of "Buy" from Analysts

Thursday, June 23, 2022 | MarketBeat

Legend Biotech Co. (NASDAQ:LEGN - Get Rating) has received an average rating of "Buy" from the six research firms that are currently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $65.20.

A number of equities research analysts recently commented on LEGN shares. BTIG Research lifted their target price on Legend Biotech from $65.00 to $75.00 in a report on Tuesday, March 1st. BMO Capital Markets began coverage on Legend Biotech in a report on Thursday, June 16th. They set an "outperform" rating and a $77.00 target price for the company. Morgan Stanley lifted their price target on Legend Biotech from $51.00 to $55.00 and gave the company an "overweight" rating in a research report on Monday, March 7th. Finally, Barclays began coverage on Legend Biotech in a research report on Tuesday, March 15th. They set an "overweight" rating and a $53.00 price target for the company.

Several institutional investors have recently bought and sold shares of LEGN. Ensign Peak Advisors Inc purchased a new stake in shares of Legend Biotech in the fourth quarter valued at approximately $89,000. Daiwa Securities Group Inc. increased its position in shares of Legend Biotech by 2,373.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,696 shares of the company's stock worth $126,000 after purchasing an additional 2,587 shares in the last quarter. AlphaCentric Advisors LLC purchased a new stake in shares of Legend Biotech during the fourth quarter worth approximately $140,000. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Legend Biotech during the fourth quarter worth approximately $210,000. Finally, Parametrica Management Ltd purchased a new stake in shares of Legend Biotech during the first quarter worth approximately $220,000.


Legend Biotech stock opened at $47.77 on Thursday. The company has a quick ratio of 3.81, a current ratio of 3.83 and a debt-to-equity ratio of 0.29. Legend Biotech has a 52 week low of $30.75 and a 52 week high of $58.00. The company has a market capitalization of $7.37 billion, a price-to-earnings ratio of -40.14 and a beta of -0.11. The stock has a 50-day moving average price of $41.35 and a 200 day moving average price of $41.37.

Legend Biotech (NASDAQ:LEGN - Get Rating) last released its earnings results on Wednesday, June 1st. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.33. Legend Biotech had a negative return on equity of 109.44% and a negative net margin of 295.68%. Research analysts anticipate that Legend Biotech will post -2.04 EPS for the current fiscal year.

About Legend Biotech (Get Rating)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.

Recommended Stories

Analyst Recommendations for Legend Biotech (NASDAQ:LEGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Legend Biotech right now?

Before you consider Legend Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.

While Legend Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastHow To Navigate The Market Downturn Like A Pro

In this episode, Kate sits down with Kyrill Astur, CEO of portfolio management firm Centerfin. Kyrill brings a background from Wall Street and hedge funds to his current role helping individual investors navigate the market challenges while investing for their future.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.